Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bonnie Hill

Nurse Practitioner, Family Louisa, KY Nurse Practitioner

NPI 1538585385 CMS profile 10433523

32 Professional Park Dr, Suite 102, Louisa, KY 41230

Open in the dashboard

General payments

$371,834

1,230 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bonnie Hill of Louisa, KY is reported in the CMS Open Payments database as having received $371,834 across 1,230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107,937 262
2024 General $89,232 242
2023 General $67,662 205
2022 General $46,561 245
2021 General $60,444 276

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bonnie Hill
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Bonnie Hill were reported at $107,937. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Bonnie Hill Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $60,444 $124 $35–$379 $132
2022 $46,561 $141 $44–$430 $149
2023 $67,662 $154 $49–$476 $160
2024 $89,232 $165 $51–$504 $164
2025 $107,937 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $281,272 672 payments
  2. Madrigal Pharmaceuticals $26,740 59 payments
  3. Gilead Sciences, Inc. $23,348 76 payments
  4. Evoke Pharma, Inc. $17,064 33 payments
  5. Aimmune Therapeutics, Inc. $13,919 47 payments
  6. Nestle HealthCare Nutrition Inc. $5,365 27 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,151 194 payments
  8. Janssen Biotech, Inc. $611 28 payments
  9. RedHill Biopharma Inc. $321 31 payments
  10. Novo Nordisk Inc $187 9 payments
  11. Other $857 54 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $267,828 228 payments
  2. Travel and Lodging $64,230 201 payments
  3. Consulting Fee $20,618 10 payments
  4. Food and Beverage $18,870 788 payments
  5. Honoraria $173 1 payment
  6. Education $116 2 payments
Products named General payments · program years 2021–2025
  1. MAVYRET $265,298 476 payments
  2. Epclusa $22,939 48 payments
  3. REZDIFFRA Liver Disease $22,354 47 payments
  4. ZENPEP $19,235 65 payments
  5. GIMOTI $14,541 30 payments
  6. LINZESS $6,255 46 payments
  7. REZDIFFRA Liver Disease $3,890 5 payments
  8. XIFAXAN $1,200 119 payments
  9. QULIPTA $773 37 payments
  10. UBRELVY $758 41 payments
  11. Other $6,304 440 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

4,340

Median for Nurse Practitioner: 389

Drug cost

$1,619,456

Median for Nurse Practitioner: $21,885

Branded share of claims

27.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 25 $281,001
Xifaxan Rifaximin Brand 64 $202,694
Rezdiffra Resmetirom Brand 31 $134,443
Linzess Linaclotide Brand 150 $121,092
Dupixent Pen Dupilumab Brand 13 $97,297
Entyvio Pen Vedolizumab Brand 15 $95,018
Mounjaro Tirzepatide Brand 82 $90,682
Relistor Methylnaltrexone Bromide Brand 26 $79,146
Gimoti Metoclopramide Hcl Brand 30 $68,717
Creon Lipase/Protease/Amylase Brand 26 $54,431

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$20,931

Medicare's payments for the services billed

Medicare patients

263

Average age 67

Services billed

563

166 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 44%
Depression 32%
COPD 30%
Chronic kidney disease 28%
Ischemic heart disease 27%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MAVYRET
$65,769 — —
GIMOTI
$7,010 30 —
ZENPEP
$5,903 — —
REZDIFFRA
$3,890 31 —
LINZESS
$2,915 150 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record